Ignite Creation Date:
2025-12-25 @ 3:07 AM
Ignite Modification Date:
2026-03-15 @ 3:25 AM
Study NCT ID:
NCT04948333
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-23
First Post:
2021-06-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Myelogenous Leukemia | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | ABL001 | View |
| None | Phase 3 | View |
| None | tyrosine kinase inhibitor | View |
| None | Chronic myelogenous leukemia (CML) | View |
| None | chronic myeloid leukemia (CML) | View |
| None | chronic myelocytic leukemia (CML) | View |
| None | chronic granulocytic leukemia (CGL) | View |
| None | cancer of the white blood cells | View |
| None | clonal bone marrow stem cell disorder | View |
| None | proliferation of mature granulocytes | View |
| None | Treatment optimization | View |
| None | Asciminib | View |
| None | European Leukemia Network (ELN) Recommendations 2020 | View |
| None | Major Molecular Response (MMR) rate at 48 weeks | View |